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ABSTRACT
Endovascular treatment of cerebral aneurysm continues
to evolve with the development of new technologies.
This review provides an overview of the recent major
innovations in the neurointerventional space in recent
years.
HISTORY OF ENDOVASCULAR TREATMENT
The neurosurgical treatment of intracranial
aneurysms dates back to 1937, when Dandy1
described microsurgical obliteration of
a posterior communicating artery aneurysm.
For decades, microsurgical clipping remained
the gold standard and foremost modality
for treatment of cerebral aneurysms.
Endovascular therapies emerged in the 1990s
with the advent of the Guglielmi detachable
coil system. This system established neuroin-
tervention as a new field, with multiple rando-
mised clinical trials demonstrating the efficacy
and safety of coil embolisation.2 3 Despite
these early favourable results, postcoiling
aneurysm recanalisation remained a challenge
in the field. For instance, Raymond et al’s4
experience with 501 cerebral aneurysms
treated with endovascular coiling demon-
strated that complete angiographic occlusion
rate was approximately only 38% at 1-year
follow-up. The data were further corroborated
by Gory and Turjman,5 whose prospective,
multicentre European study of 404 aneurysms
treated with Nexus detachable coils
(ev3-Covidien, Irvine, California, USA),
showed 22% neck remnant and 30% aneurys-
mal remnant, with a 17.7% recanalisation rate
and 21.6% thrombosis rate at 13 months
angiographic follow-up.
To address these shortcomings, the neuroen-
dovascular space quickly experienced significant
technological advancements aimed at improv-
ing the different properties of a coil, including
coil lengths, shapes, softness and detachment
zones. These developments have translated to
improvements in clinical outcomes of cerebral
aneurysms treated with coiling. For example,
HydroCoils (MicroVention, Tustin, California,
USA) have allowed for treatment of more
complex aneurysmal configurations with a
reduction in recurrence rates compared with
bare-platinum coils.6 7 Additionally, new neu-
roendovascular devices such as intracranial
stents and balloons were developed to
augment coil embolisation. In balloon-
assisted coil embolisation, typically a compli-
ant balloon is positioned across the neck of
the aneurysm to provide a scaffold protecting
the parent artery while coils are deployed
through a microcatheter into the aneurysm
sac. This reduces the risk of coil prolapse
into the parent vessel and can also provide
immediate protection in an event of intra-
procedural aneurysm rupture during the
coiling due to the ability to achieve endovas-
cular proximal control with balloon inflation.
Comparatively, stent-assisted coil embolisa-
tion was developed to improve the occlusion
rate and coil packing density of wide-necked
as well as large and giant aneurysms. During
this process, the stent (similar to a balloon)
is positioned across the aneurysm neck, pro-
viding a scaffold to protect the parent artery.
This minimises coil loop prolapse and allows
for higher density coil packing, leading to a
reduction in recurrence rates and higher
rates of angiographic occlusion.8–10
Despite these technological advancements
in coil embolisation, aneurysms with large
diameters (>10 mm), wide necks, unfavour-
able dome-to-neck ratios (<2) and fusiform
configuration remain therapeutic challenges
and dilemmas, with as high as >20% poor
outcome (aneurysm recurrence or treat-
ment-related morbidity/mortality) associated
with the management of large/giant aneur-
ysms.11 12 To meet these challenges, device
innovations have ushered in new therapeutic
concepts, including flow diversion and intra-
saccular flow disruption.
FLOW DIVERSION REVOLUTION
The concept of flow diversion serendipit-
ously stemmed from the lessons garnered
from stent-assisted coil embolisation. When
research studies demonstrated that denser
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coil packing with less coil prolapse into the parent vessel
correlated with improved clinical and radiographic out-
comes, fluid dynamic analysis revealed that endovascular
stents actually accelerated aneurysmal thrombosis and
alteration in blood flow into the aneurysm from the
parent vessel.9 13 14 Flow diversion is fundamentally
based on two concepts illustrated in figure 1: (1) the
placement of a high-mesh density stent in the parent
vessel disrupts blood flow into the aneurysm and (2) the
stent provides a scaffold for which endothelium can
grow, subsequently isolating the aneurysm from the
parent circulation.15 Flow diversion thus allows for
progressive intra-aneurysmal thrombosis over time with
subsequent radiographic obliteration of the aneurysm.
The advantage of endoluminal flow diversion over endo-
saccular coiling is the ability to treat the weakened
abnormal arterial wall by providing a scaffold for neoen-
dothelialisation to occur. This neoendothelialisation
process results in a durable occlusion of the aneurysm
that often provides a curative outcome as compared with
the known recurrence associated with coiling. Figure 2
demonstrates a case example of a large left-sided cavern-
ous internal carotid artery (ICA) aneurysm that was
treated with a flow diverter deployed within the parent
ICA and evidence of complete aneurysm occlusion on
the 6-month follow-up angiography. Additionally, with
the endoluminal approach, the aneurysm sac does not
need to be accessed during the treatment, which subse-
quently eliminates the risk of intraprocedural aneurysm
rupture inherent with endosaccular coiling.
The first introduction of flow diversion into the
neuroendovascular space was in 2007, with the invention
of the Pipeline Embolization Device (PED; Medtronic
Neurovascular, Irvine, California, USA).16 Since then,
a plethora of flow diverters have entered the neurointer-
ventional field including the Silk flow diverter (Balt
Extrusion, Montmorency, France), Flow-Redirection
Endoluminal Device (FRED; MicroVention, Tustin,
California, USA), Surpass (Stryker Neurovascular,
Freemont, California, USA), Tubridge (MicroPort
Medical, Shanghai, China) and p64 Flow Modulation
Device (Phenox, Bochum, Germany). Most of these flow
diverters are commercially available in Europe and
South America. In the USA, however, PED is the only
available flow diverter after its approval by the Food and
Drug Administration (FDA) in 2011.17
Pipeline Embolization Device
The PED is a braided mesh designed with 48 strands
consisting of 25% platinum–tungsten and 75% cobalt–
chromium–nickel alloy. When fully deployed, the PED
provides 35% metallic surface-area coverage with pore
size of 0.02–0.05 mm2 at nominal vessel diameter.15 The
PED is available in sizes ranging from 2.5 to 5.0 mm in
diameter (in 0.25 mm increments) and 10–35 mm in
length (in 2 mm increments from 10 to 20 mm, and
5 mm increments from 20 to 35 mm). The PED delivery
system comes attached to a 0.016″ diameter stainless
steel delivery wire, with the segment where it is mounted
Figure 1 Flow diversion concept: placement of a high-mesh density stent (flow diverter) in the parent vessel disrupts blood flow
into the aneurysm (A and B), allowing for progressive intra-aneurysmal thrombosis over time with subsequent obliteration of the
aneurysm (C and D). Additionally, the flow diverter provides a scaffold for neoendothelialisation, which treats the weakened
abnormal arterial wall and isolates the aneurysm from the parent circulation resulting in durable occlusion of the aneurysm (E).
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being 0.008″ thick. It is delivered via a 0.027″ delivery
microcatheter, such as the Marksman (Medtronic
Neurovascular, Irvine, California, USA) or a similar size
microcatheter. The second-generation PED, named
Pipeline Flex (PED Flex), received the European CE
mark of approval in March 2014 and subsequently
received FDA approval in February 2015. Its design
includes numerous delivery system changes to enhance
device opening and provide additional safety with a
resheathing feature.18 The PED’s on-label usage as dic-
tated by the FDA is limited to the treatment of large or
giant (≥10 mm) wide-necked intracranial aneurysms
from the petrous to the superior hypophyseal segments
of the ICA.17
Clinical experience worldwide with PED has demon-
strated the effectiveness, durability, safety and cost-effect-
iveness of endovascular endoluminal reconstruction
primarily in large and giant aneurysms. Initial reports
from Buenos Aires and Budapest series demonstrated
complete radiographic occlusion rates in the 90–93%
range at 6 months follow-up angiogram.19 20 These
studies paved the way to the PED for the Intracranial
Treatment of Aneurysms Trial (PITA), which showed
93.3% angiographic occlusion rates at 6 months (28 of
30 aneurysms), with 6.5% of patients having major
stroke or neurological complication (2 of 31 patients).16
Similarly, the PED for Uncoilable or Failed Aneurysms
(PUFs) multicentre clinical trial that led to the FDA pre-
market approval of the PED in 2011, demonstrated in
108 patients across 10 prospective centres high rates of
primary efficacy (81.8% of aneurysm with complete
occlusion at 6 months) with low complication rate (5.6%
of patients with major strokes or neurological injury at
180 days).21 Taken together, all of the trials demon-
strated relatively high rates of aneurysm occlusion (81.8–
93.3%) with low rates of major morbidity and mortality
(0–6.5%).16 19–21
Other subsequent studies for the on-label usage of
PED have corroborated the trial data at the institutional
level, with similar rates of radiographic success with low
rates of postprocedural morbidity and mortality.22
Studies have further demonstrated the cost-effectiveness
of using PED as advantageous over traditional
stent-assisted coiling of large anterior circulation aneur-
ysms (27.1% cost reduction per millimetre of aneurysm
treated in the PED group compared with stent-assisted
coiling).23 Treatment of large and giant proximal ICA
aneurysms using PED also requires less radiation, less
fluoroscopy time and less contrast administration than
standard coiling techniques, with an average radiation
dose of 2840 mGy with PED treatment compared with
4010 mGy with traditional coiling techniques.24
Although PED is FDA approved for large and giant
intracranial aneurysms, these aneurysms only encompass
a small fraction of all intracranial aneurysms. In contrast,
over 80% of all cerebral aneurysms found in the general
population are <10 mm in size.25 26 There is considerable
documentation in the literature that the majority of rup-
tured aneurysms are smaller than 10 mm.27 Treatment of
small aneurysms (<10 mm) with flow diverters may be
advantageous over traditional endosaccular modalities.
Lin and colleagues retrospectively reviewed a prospective,
single-centre aneurysm database to identify 41 patients
with 44 PED cases. In this series, mortality was reported
in 2.3% while by 6 months post-PED implantation, angio-
graphic success was observed in 80%.28 This experience
with PED treatment for small ICA aneurysms is compar-
able to the few published reports on this experience, with
mortality range of 0% observed by Chan et al,29 and 11%
observed by Lubicz et al,30 which is comparable with the
PED experience for large and giant aneurysms with
reported mortality rates up to 5.5%.
A wealth of experience has been garnered in the neu-
roendovascular space with the PED since its introduc-
tion, such that treatment of large and giant ICA
aneurysms with flow diversion is now a widely accepted
standard approach. As a result of the success with PED
treatment of these complex aneurysms, there is also an
expansion of interest and data supporting the safety as
well as efficacy of PED treatment in an ‘off-label’
manner with small anterior circulation aneurysms as
well as select posterior circulation aneurysms.31–33
Surpass flow diverter
The Surpass flow diverter is similar to the PED in design
consisting of a braided mesh constructed of cobalt–
Figure 2 Flow diversion treatment of a large left cavernous aneurysm with complete occlusion of the aneurysm demonstrated at
6-month follow-up angiogram.
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chromium alloy intertwined with platinum–tungsten
wires for visibility. Compared with PED, the Surpass has
a lower porosity and is designed to maintain constant
pore density over various diameters of the device.
Additionally, the Surpass flow diverter exists in fewer
sizes with only 3, 4 and 5 mm diameter options. The 3
and 4 mm devices have 72 wires, and the 5 mm device has
96 wires. Unlike the PED, the Surpass device is preloaded
at the distal end of a microcatheter delivery system that
consists of a 0.040″ inner diameter (ID) delivery mico-
catheter and pusher. The entire Surpass delivery system is
advanced over a 0.014″ microwire inserted through the
pusher. The implant is deployed by a combination of
advancing the pusher and unsheathing the
microcatheter.34
Wakhloo et al35 reported the largest study on safety
and efficacy of Surpass, with a prospective, multicentre,
non-randomised, single-arm design of 165 patients with
190 intracranial aneurysms of the anterior and posterior
circulations enrolled from 24 centres. Successful deploy-
ment of the Surpass flow diverter was observed in 98%
of the aneurysms. Follow-up angiography available in
158 (86.8%) intracranial aneurysms showed 100% occlu-
sion in 75% of the cases at radiographic follow-ups.
Permanent neurological morbidity and mortality were
6% and 2.7%, respectively. Morbidity occurred in 4%
and 7.4% of patients treated for aneurysms of the anter-
ior and posterior circulation, respectively. These data
demonstrate that the clinical safety profile is similar to
that of stent-assisted coil embolisation and PED treat-
ment with high rates of radiographic occlusion.35
Colby and colleagues reported the initial North
American experience with Surpass. In this study, 20
patients with ICA aneurysms ≥10 mm with ≥4 mm neck
were treated as part of the Surpass IntraCranial
Aneurysm Embolization System Pivotal Trial (the SCENT
trial; Stryker).36 The Surpass device was implanted in
19/20 (95%) cases. Of 19 cases, a single device was used
in 18 cases (95%) and two devices in only 1 case (5%).
Balloon angioplasty was performed in 8/19 cases (42%).
Complete aneurysm neck coverage and adequate vessel
wall apposition was obtained in all 19 cases without
acute morbidity or mortality. An advantage of Surpass
flow diverter is the Surpass delivery system that allows for
a torque-free, over-the-wire deployment of the device.36
Additionally, this system provides the safety of maintain-
ing a continuous endoluminal wire access that is
uncoupled from the device deployment.
Other flow diverters
Silk
The Silk is a self-expandable stent consisting of a tightly
woven structure, supplied with a soft microcatheter and
has resheathing and relocation abilities. For the majority
of studies in the literature, Silk is used for large and
giant neck fusiform aneurysms with a wide neck
(dome-to-neck ratio of <2 mm or neck >4 mm). Strauss
and Maimon37 retrospectively reviewed patient data
from 2008 to 2013 and identified 60 patients with 67
aneurysms (15 posterior circulation, 52 anterior circula-
tion). They concluded a ‘good’ angiographic result in
88% or 53/60 aneurysms, with a good outcome defined
as complete or near-complete angiographic occlusion at
15 months. The group identified aneurysm size as a posi-
tive predictor of complication rate (0% in smaller aneur-
ysms, 16.7% in large aneurysms and 42.9% in giant
aneurysms). Giant aneurysms of the posterior circulation
had unfavourable results, with 57% complication rate
due to brainstem ischaemia secondary to perforator
occlusion.37 These data are further corroborated by
Lubicz et al,38 who reported a 11% delayed complication
rate with overall neurological morbidity of 5.5%;
however, all complications were reported with the first-
generation Silk device. In an eight-centre study in
Canada by Shankar and colleagues, perioperative mor-
bidity and mortality were 8.7% and 2.2%, respectively. At
the last available follow-up, 83.1% of the aneurysms were
either completely or near completely occluded, with the
rate of complications was higher for fusiform aneurysms
(p<0.001).39
Taken together, these data show a trend towards better
outcomes for smaller and anterior circulation aneurysms
and overall consistent radiographic outcomes for flow
diversion of large and/or fusiform aneurysms with the
Silk device.
Flow-Redirection Endoluminal Device
The FRED system is flow diverter with a compliant
closed-cell paired stent (aka ‘stent within a stent’) com-
posed of single wire braid self-expanding nickel titan-
ium. Initial experience with this device remains limited.
Diaz et al40 reviewed 13 patients with 14 treated aneur-
ysms. Although no long-term angiographic data are
available, there were no technical or immediate postpro-
cedural complications. The authors concluded the
device was technically easy to deploy and articulates the
ability for the device to be recaptured after partial
deployment and to maintain its internal shape in tortu-
ous vessels as particular advantage. Long-term clinical
and angiographic clinical studies are necessary to
further study this device.
p64
The p64 Flow Modulation Device is a braided mesh tube
composed of a 64 nickel–titanium nitinol alloy. The
device is compatible with a 0.027″ ID microcatheter. It is
available in sizes 2.5–5 mm diameter with 12–36 mm
length. There are limited clinical data on this flow diver-
ter, with an initial experience and technical aspects
reported by Briganti and colleagues. In their series of
six intracranial aneurysms, immediate post-treatment
angiography showed reduced flow into all aneurysms,
although no long-term angiographic data are available.41
The authors reported no periprocedural technical com-
plications and no early or delayed aneurysm rupture, no
ischaemic or haemorrhagic complications, and no
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neurological morbidity or deaths. The authors note that
the mechanical detachment feature, with 100% retriev-
ability, is a potential advantage of this new device.41
Tubridge flow diverter
The Tubridge is a flow diverter developed by MicroPort
Medical Company and is a braided, self-expanding
stent-like device with flared ends. A large Tubridge
(diameter ≥3.5 mm) is braided with 62 nickel–titanium
microfilaments and 2 platinum–iridium radiopaque
microfilaments, whereas a smaller Tubridge (diameter
<3.5 mm) is composed of 46 nitinol and 2 platinum–
iridium microfilaments. Initial experience from Zhou
et al42 on 28 patients with large or giant ICA aneurysms
showed a 0% morbidity and mortality rate periprocedu-
rally. At a mean follow-up of 10 months, 72% of the
aneurysms were completely occluded and 24% were
improved, with 4% showing no significant change.42
After approval from the Chinese FDA, the device is cur-
rently being studied in a multicentre, randomised, con-
trolled clinical trial.43 In this study, Zhou et al will enrol
124 patients and randomise into a treatment group con-
sisting of Tubridge or Tubridge with coils versus a
control group treated with stent-assisted coiling.
INTRASACCULAR FLOW DISRUPTION AND THE WOVEN
ENDOBRIDGE DEVICE
Flow diversion has proven promising to overcome limita-
tions of traditional endovascular coiling techniques for
the treatment of sidewall aneurysms; however, the
management of large bifurcation aneurysms remains a
challenge. For these bifurcation aneurysms, coiling with
adjunctive devices such as temporary balloon protection
or stent assistance are associated with increased proced-
ural complexity, which lead to a higher chance of
complications. Additionally, use of stents requires
periprocedural dual-antiplatelet therapy with inherent
risks of haemorrhage. In this context, a new device was
developed to provide an innovative alternative strategy
via intrasaccular flow disruption called the Woven
EndoBridge (WEB; Sequent Medical, Aliso Viejo,
California, USA). The WEB is a self-expanding, oblate,
braided mesh of nitinol wires that is deployed into the
aneurysm sac itself (figure 3). The initial WEB device
consisted of a dual layer (WEB DL) design of inner and
outer braids; however, this has since evolved to a single
layer (WEB SL) device with a higher number of nitinol
wires providing similar flow disruption effects.44 Prior to
detachment of the WEB device, it can be fully retrieved.
Additional modifications of the WEB SL device include a
spherical shape (WEB SLS) and enhanced visualisation
(WEB EV) provided by platinum-cored nitinol wires.
Once a WEB device is deployed within the aneurysm sac,
the WEB modifies the blood flow at the aneurysm neck,
which induces thrombosis within the aneurysm. Figure 4
demonstrates two case examples of middle cerebral artery
(MCA) bifurcation aneurysms treated with the WEB
device.
Several retrospective institutional studies in Europe
have demonstrated the initial safety and efficacy of
the WEB device.44–47 Given the promising data, two
prospective, good clinical practice series were con-
ducted in Europe: WEBCAST and French Observatory.
These single-arm, prospective, multicentre studies
included ruptured and unruptured bifurcation
Figure 3 WEB intrasaccular flow disruption system. SL, single layer; WEB, Woven EndoBridge; WEB SLS, WEB SL device with
a spherical shape. Images provided by Sequent Medical.
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aneurysms located in the basilar artery, middle cere-
bral artery, anterior communicating artery and ICA
terminus.48 Postoperative, 6-month (in WEBCAST)
and 1-year aneurysm occlusion was independently
evaluated with a three-grade scale: complete occlu-
sion, neck remnant and aneurysm remnant. A total of
113 patients with 114 aneurysms were treated. There
was no mortality at 1 month, and morbidity was 2.7%.
At 1 year, complete aneurysm occlusion was observed
in 56.0%, neck remnant in 26.0% and aneurysm
remnant in 18.0%. Worsening of aneurysm occlusion
between the procedure and 12 months was observed
in 2.0% and between 6 months and 1 year in 7.1%.48
The combination of these two prospective studies repre-
sents the largest series of WEB cases in the literature. The
advantage of the WEB device is the combination of an
endosaccular approach with flow diversion. This elimi-
nates the need for dual antiplatelet therapy required for
endoluminal devices and subsequently allows use in the
ruptured aneurysm setting with subarachnoid haemor-
rhages. Although the data are encouraging, the availabil-
ity of the WEB device is still limited primarily to Europe
and South America. In the USA, the multicentre clinical
trial for premarket approval of the WEB completed enrol-
ment in November 2015 and the data from the trial are
still being collected.
NEUROENDOVASCULAR CATHETER ACCESS SYSTEM
As neurointervention evolves with innovative devices
such as flow diverters and intrasaccular devices, catheter
access systems have also become more sophisticated.
Fundamental to any neurointervention is the need for a
stable catheter access and delivery system that offers
varying degrees of trackability, distal and proximal
support, and precise distal targeting. In essence,
increased guide catheter support is required for proce-
dures with larger device delivery systems, tortuous
anatomy and distal targets.
Classically, neurointerventions were performed using a
biaxial system consisting of a relatively rigid guide cath-
eter (eg, Envoy) positioned in the cervical ICA and a
small flexible microcatheter that was advanced intracra-
nially to the target of interest. Often the microcatheter
has to be advanced a considerable distance from the
supporting guide catheter, thereby reducing the control
and tactile feedback for the operator and increasing the
propensity for unwanted slack in the system. These lim-
itations are amplified in older patients with significant
vessel tortuosity, and it can lead to technical failures that
necessitate alternative more invasive approaches such as
direct carotid puncture.
There has been a paradigm shift in the design and
approach to catheter support systems for cases of flow
diversion from a classic biaxial set-up with cervical posi-
tioning of guide catheters to a more robust triaxial
system with intracranial positioning of intermediate
support catheters. This is secondary to the comparatively
larger size of the flow diverter delivery microcatheter
(0.027″ ID for the PED) and the significant intradeploy-
ment manipulations required for proper device implant-
ation. The Navien (Medtronic Neurovascular, Irvine,
Figure 4 WEB treatment of MCA bifurcation aneurysms. Top row is a small left MCA bifurcation aneurysm. Bottom row is a
large right MCA bifurcation aneurysm. WEB, Woven EndoBridge. Images provided by Sequent Medical.
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California, USA) is a newer generation 5 French (0.058″
ID) distal intracranial catheter that is highly trackable
and atraumatic with a large bore lumen that can accom-
modate 0.027″ ID delivery microcatheters used for flow
diverters with added room for flush and contrast injec-
tions. There has been significant experience with the
Navien for use in a variety of endovascular aneurysm
treatments, including PED as well as stent-assisted
coiling. These experiences demonstrate successful track-
ability of the catheter consistently to intracranial loca-
tions such as the ICA and MCA despite vessel
tortuosity.49 50 The Navien catheter has also been instru-
mental when used as a salvage technique for cases
where PED opening fails with standard deployment
manoeuvres.51
This paradigm shift towards more robust multiaxial
catheter support systems has ushered the development
of additional new intermediate support catheters similar
to the Navien catheter. One such example is the Catalyst
class of intermediate catheters (Stryker Neurovascular,
Freemont, California, USA). The 5 French Catalyst has
demonstrated significant advantages of enhanced track-
ability with reliable stable intracranial support for deliv-
ery of modern neuroendovascular devices, including
flow diverters such as the PED Flex and Surpass, as well
as the intrasaccular devices such as the WEB (senior
authors’ experience, unpublished data). The import-
ance of stable catheter support systems translates to
improved safety and ease for sophisticated neurointer-
ventional treatments.
PENDING NEW TECHNOLOGY
An array of potential new technology is on the horizon
for the neurointerventional field. These include coated
flow diverters for reduced thrombogenicity, self-
expanding three-dimensional mesh endosaccular device
called the Medina (Medtronic Neurovascular, Irvine,
California, USA), smaller profile WEB devices to address
broader range of aneurysm sizes (figure 5), and an add-
itional new intrasaccular flow disrupter called the Artis
device (Medtronic Neurovascular, Irvine, California,
USA). These new technologies will continue to expand
the neuroendovascular tools available to treat a wide
variety of aneurysm types with improved safety and
efficacy. It is fair to say the management of intracranial
aneurysms is constantly evolving, with sophisticated tech-
nology at the forefront of innovation.
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